200 First Street SW Rochester, MN55905 United States Visit Website E-mail: mayoadc@mayo.edu Brain Banks Home ...

Can targeting α-synuclein slow the course of Parkinson’s disease? Despite years of trying, success has eluded scientists thus far. At the AD/PD conference, held March 17-21 in Copenhagen, Denmark, ...

In early symptomatic Alzheimer’s disease, amyloid immunotherapy confers but a slight cognitive benefit. Some scientists speculate that one reason could be the presence of other pathologies in the ...

Yes, you read that correctly, scientists are giving acetylcholine receptor drugs another whirl in Alzheimer’s. At the AD/PD conference, held March 17–21 in Copenhagen, Denmark, Manfred Windisch of NSC ...

Clinicians have started using blood tests of p-tau217, a marker of amyloid plaques, to help diagnose AD in routine patient care, not just research studies. Alas, at AD/PD 2026, held March 17-21 in ...

The MAPT haplotypes H1 and H2 are defined by a large inversion polymorphism on chromosome 17. The HI haplotype has been consistently linked to risk for several neurodegenerative diseases, particularly ...

Blood tests for Alzheimer’s disease are rapidly transforming the way clinicians diagnose the disease. Still, some scientists urge caution when interpreting results, arguing that the meaning of a ...

Exercise helps stave off Alzheimer’s disease, but exactly how it does so is murky. In the February 18 Cell, scientists led by Saul Villeda at the University of California, San Francisco, offered one ...

In trying to treat neuroinflammation, scientists need better ways to visualize microglia in the brains of living people. Current microglial PET tracers target the mitochondrial transporter TSPO, but ...

According to a recent study, the view that Alzheimer’s disease damages the brain irreversibly might need to change. In December 22 Cell Reports Medicine online, scientists led by Andrew Pieper of Case ...

As amyloid immunotherapy enters clinical care in more countries, providers the world over are eager for more information on how well it works, and especially how safe it is. To collect such data in ...

On November 24, Novo Nordisk announced that the GLP-1 mimetic semaglutide had failed to slow progression of Alzheimer’s disease in two Phase 3 trials. Even though the cat was out of the bag, ...